title: FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
abstract: OBJECTIVE
  The interaction of Fc fragments of antibodies with the Fcgamma receptors is an essential checkpoint in antibody-dependent cellular cytotoxicity (ADCC). Specific polymorphisms at position 158 enhance FcgammaRIIIa affinity for IgG1 and are associated with improved clinical outcome in lymphoma patients treated with IgG1 anti-CD20 antibody. The role of ADCC in the therapeutic effects of the alpha-epidermal growth factor receptor (EGFR) mAb, cetuximab, in patients with squamous cell carcinoma of the head and neck (SCCHN) is poorly defined. We employed three SCCHN cell lines to test two hypotheses: (1) SCCHN is susceptible to cetuximab-mediated ADCC, (2) efficacy of ADCC is associated with polymorphisms at position 158 of FcgammaRIIIa.
  
  
  METHODS
  FcgammaRIIIa-158 polymorphisms were determined for healthy donors, and their purified NK cells were used as effector cells against three SCCHN cell lines in ADCC assays. Cytotoxicity levels were compared for each polymorphism class. Proliferation and cell cycle assays were done to examine the direct effects of cetuximab.
  
  
  RESULTS
  Our results indicate that SCCHN is susceptible to cetuximab-mediated ADCC in vitro. NK cytotoxic efficiency correlates with donor 158-polymorphisms in FcgammaRIIIa. Overall cytotoxicity was greatest for individuals having a single V allele when compared to homozygous F/F individuals; the cumulative percent cytotoxicity for each polymorphism among the cell lines was 58.2% V/V, 50.6% V/F, and 26.1% F/F (P < 0.001). Additionally, the presence of a V allele correlated with superior natural cytotoxicity against NK sensitive targets.
  
  
  CONCLUSIONS
  These data have both prognostic and therapeutic relevance and support the design of a prospective trial to determine the influence of FcgammaRIIIa polymorphisms on the clinical outcome of patients with SCCHN treated with alpha-EGFR mAbs.
authors.affiliation: Department of Otorhinolaryngology/Head and Neck Surgery, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201, USA. rtaylor@smail.umaryland.edu
authors.forename: Rodney J
authors.initials: RJ
authors.lastname: Taylor
authors.forename: Siaw-Lin
authors.initials: SL
authors.lastname: Chan
authors.forename: Aaron
authors.initials: A
authors.lastname: Wood
authors.forename: Caroline J
authors.initials: CJ
authors.lastname: Voskens
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Wolf
authors.forename: Wei
authors.initials: W
authors.lastname: Lin
authors.forename: Andrei
authors.initials: A
authors.lastname: Chapoval
authors.forename: Dan H
authors.initials: DH
authors.lastname: Schulze
authors.forename: Guoliang
authors.initials: G
authors.lastname: Tian
authors.forename: Scott E
authors.initials: SE
authors.lastname: Strome
mesh_terms: D000483:Alleles; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000920:Antibody-Dependent Cell Cytotoxicity / Q000235:genetics* / Q000276:immunology; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D000068818:Cetuximab; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism*; D011110:Polymorphism, Genetic; D017452:Receptors, IgG / Q000235:genetics* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C496124:FCGR3A protein, human; D017452:Receptors, IgG; D000068818:Cetuximab